What does 99% purity mean for peptides?
≥99% purity on a research-peptide certificate of analysis means that 99% or more of the total UV-detectable material in the HPLC chromatogram corresponds to the target peptide peak; the remaining ≤1% is distributed across impurity peaks (sequence variants, deletion peptides, deamidation products, process-related impurities). Higher purity reduces the impurity profile that downstream experiments might inadvertently characterise.
What the research literature says
The ≥99% threshold is one common research-peptide quality standard, alongside the slightly lower ≥98% threshold also widely used in the supply tier. Both thresholds are expressed as the percentage of total UV-detectable peak area in the HPLC chromatogram at the 214 nm peptide-bond wavelength, measured by integration of all detected peaks and the ratio of target-peak area to total area.
The ICH Q3 guideline series covers impurity-threshold considerations in pharmaceutical drug substances: identification threshold (above which an impurity must be identified by structure), qualification threshold (above which the impurity must be qualified for safety), and reporting threshold (above which the impurity must be reported on the COA). The USP <1086> general chapter consolidates the impurity-management framework. Research-peptide supply at ≥99% purity sits well below the typical pharmaceutical reporting thresholds for individual impurities.
The practical implication: a ≥99% purity peptide has ≤1% total impurity content, with each individual impurity peak typically below 0.5% (often well below — many sit at 0.1-0.3%). Pharmaceutical-grade products carry tighter specifications (≥99.5% purity is common in the pharmaceutical tier) plus full impurity-identification dossiers; research-grade products with ≥99% purity provide the analytical chromatogram on the COA so buyers can inspect the impurity profile directly.
Why this matters in research context
Purity matters because some impurity classes can confound experimental outcomes. Sequence variants might have similar but distinguishable pharmacology that competes with the target compound at low concentrations. Process-related impurities can introduce experimental artifacts in sensitive assays. The higher the purity, the cleaner the signal — but the trade-off is cost. For most research applications, ≥98% is adequate; for applications sensitive to trace impurities, ≥99% is the operational standard. The COA inspection is the substantive verification step.
Related compounds
- Lab results page — per-batch COA access framework
- Full catalog — per-compound purity thresholds in each product page
Related research questions
References
- ICH Q3A(R2) — Impurities in New Drug Substances. Identification, qualification, and reporting thresholds for pharmaceutical impurities. International Council for Harmonisation.
- USP <1086> Impurities in Drug Substances and Drug Products. Framework for impurity management on certificates of analysis. United States Pharmacopeia.
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.